Industry News
Pharmaceutical Industry News
Zhejiang Huahai Pharmaceutical has…
Zhejiang Huahai Pharmaceutical has hired a former FDA staffer as its new chief quality officer, as the company struggles to resolve compliance issues with the FDA at a key manufacturing facility.
Clinical teams have long used real…
Clinical teams have long used real world evidence to understand how a drug works. Now commercial teams can mine evidence from unstructured data to drive action.
A bipartisan bill reintroduced by…
A bipartisan bill reintroduced by three senators aims to increase transparency around foreign influence on the United States’ drug supplies, marking a potential first step to imposing restrictions.
Vanda Pharmaceuticals is…
Vanda Pharmaceuticals is sponsoring an IndyCar to fuel awareness of its motion sickness pill, Nereus. The biotech backed the No. 47 car to represent its end of the multi-decade wait for a prescription therapy.
Gilead Sciences Canada and The…
Gilead Sciences Canada and The Local Collective worked up a bronze-winning campaign for HIV med Descovy featuring AI-generated animals.
The FDA has approved Merck’s…
The FDA has approved Merck's internally developed cholesterol-lowering treatment Lipfendra for adults with hypercholesterolemia, or high levels of "bad" cholesterol. The drug, which is the first oral PCSK9 inhibitor to reach the market, has been
As Pfizer and Moderna have tied…
As Pfizer and Moderna have tied off certain threads in their separate webs of mRNA patent litigation, Sanofi has opened a new front to challenge the companies’ blockbuster COVID-19 vaccines.
The European Commission has…
The European Commission has granted marketing authorization for Novo Nordisk’s Wegovy pill for people with obesity or who are overweight. The approval comes as Novo’s weight-loss rival, Eli Lilly, awaits European clearance for its oral
As AI, data and rising HCP…
As AI, data and rising HCP expectations redefine medical affairs, leaders need a more connected model for turning insight into action.
Merck & Co.’s almighty…
Merck & Co.’s almighty Keytruda has become the first PD-1 inhibitor to show a benefit as a single agent for the front-line treatment of a subtype of endometrial cancer.
As trial complexity rises, finance…
As trial complexity rises, finance modernization is becoming a strategic imperative for speed, site trust and operational resilience.
With a midstage peek at the data…
With a midstage peek at the data on Veradermics’ oral formulation of the molecule behind the ubiquitous hair regrowth treatment Rogaine, analysts are feeling increasingly confident that the company is a cut above the rest
Johnson & Johnson reported its…
Johnson & Johnson reported its fifth straight quarter with revenue growth of at least 6%. This surge has come despite the loss of patent protection for Stelara. Compensating for the shortfall is Tremfya, which topped
The clinical blueprint for Merck…
The clinical blueprint for Merck & Co.’s prized TROP2-directed antibody-drug conjugate, sac-TMT, could add a missing piece thanks to a landmark achieved by its partner, Kelun-Biotech.
Two years after its central role…
Two years after its central role in the Paris Olympics in France, Sanofi is back in its home country once again supporting sport.
Generative AI specialist Insilico…
Generative AI specialist Insilico Medicine has teamed up with another biopharma company, this time CDMO Bora Pharmaceuticals. The collaboration could ultimately be worth $2.5 billion if milestones are reached.
The FDA has approved a new small…
The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard-of-care for patients with breast cancer.
In an era of continued addiction…
In an era of continued addiction risk, non-opioid pain therapies are gaining traction, but access barriers persist. Here’s what’s standing in the way.
Senior Director Kate Woda breaks…
Senior Director Kate Woda breaks down what attendees can expect at the Partnerships with Sites Summit, happening Sept. 14, 2026 in Boston, MA.
Chai Discovery, an A.I. Drug Start-Up, Raises $400 Million
The fund-raising values the company at $3.8 billion and underscores investor interest in using artificial intelligence to tackle problems like drug discovery.